The possible role of antimicrobial proteins in obesity-associated immunologic alterations

References

• Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-209
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444(7121):840-6
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444(7121):860-7
   PubMed Web of Science ®Google Scholar
• Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008;14(12):1225-30
   PubMed Web of Science ®Google Scholar
• Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012;18(3):363-74
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011;121(6):2111-17
   PubMed Web of Science ®Google Scholar
• Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012;8(12):709-16
   PubMedGoogle Scholar
• Vonghia L, Michielsen P, Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci 2013;14(10):19867-90
   Google Scholar
• Borén J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med 2013;274(1):25-40
   PubMed Web of Science ®Google Scholar
• Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest 2007;117(1):89-93
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Delproposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008;57(12):3239-46
   PubMed Web of Science ®Google Scholar
• Bourlier V, Zakaroff-Girard A, Miranville A, et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 2008;117(6):806-15
   PubMed Web of Science ®Google Scholar
• Sengenès C, Miranville A, Lolmède K, et al. The role of endothelial cells in inflamed adipose tissue. J Intern Med 2007;262(4):415-21
   Google Scholar
• Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003;24(6):276-83
   PubMedGoogle Scholar
• Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92(3):1023-33
   PubMed Web of Science ®Google Scholar
• Peng Y, Rideout D, Rakita S, et al. Diet-induced obesity associated with steatosis, oxidative stress, and inflammation in liver. Surg Obes Relat Dis 2012;8(1):73-81
   Google Scholar
• Nov O, Shapiro H, Ovadia H, et al. Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS One 2013;8(1):e53626
   Google Scholar
• Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002;57(5):M326-32
   PubMed Web of Science ®Google Scholar
• Cesari M, Kritchevsky SB, Baumgartner RN, et al. Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr 2005;82(2):428-34
   Google Scholar
• Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009;58(12):2731-40
   PubMed Web of Science ®Google Scholar
• Märker T, Sell H, Zillessen P, et al. Heat shock protein 60 as a mediator of adipose tissue inflammation and insulin resistance. Diabetes 2012;61(3):615-25
   PubMed Web of Science ®Google Scholar
• Ostrowski K, Rohde T, Zacho M, et al. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 1998;508(3):949-53
   PubMed Web of Science ®Google Scholar
• Scheele C, Nielsen S, Kelly M, et al. Satellite Cells Derived from Obese Humans with Type 2 Diabetes and Differentiated into Myocytes In Vitro Exhibit Abnormal Response to IL-6. PLoS One 2012;7(6):e39657
   Google Scholar
• El-Kadre LJ, Tinoco AC. Interleukin-6 and obesity: the crosstalk between intestine, pancreas and liver. Curr Opin Clin Nutr Metab Care 2013;16(5):564-8
   Google Scholar
• Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56(7):1761-72
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Tang L, et al. T-lymphocyte responses to intestinally absorbed antigens can contribute to adipose tissue inflammation and glucose intolerance during high fat feeding. PLoS One 2010;5(11):e13951
   Google Scholar
• Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3(9):559-72
   PubMed Web of Science ®Google Scholar
• Parks BW, Nam E, Org E, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab 2013;17(1):141-52
   PubMed Web of Science ®Google Scholar
• Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012;489(7415):231-41
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Tang L, et al. T-lymphocyte responses to intestinally absorbed antigens can contribute to adipose tissue inflammation and glucose intolerance during high fat feeding. PLoS One 2010;5(11):e13951
   Google Scholar
• Osto M, Zini E, Franchini M, et al. Subacute endotoxemia induces adipose inflammation and changes in lipid and lipoprotein metabolism in cats. Endocrinology 2011;152(3):804-15
   Google Scholar
• Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292(3):E740-7
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega F, Serino M, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012;36(11):1442-9
   PubMed Web of Science ®Google Scholar
• Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009;32(12):2281-7
   PubMed Web of Science ®Google Scholar
• Clemente-Postigo M, Queipo-Ortuño MI, Murri M, et al. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. J Lipid Res 2012;53(5):973-8
   PubMed Web of Science ®Google Scholar
• Monte SV, Caruana JA, Ghanim H, et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 2012;151(4):587-93
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Fernández-Real JM. Antimicrobial-sensing proteins in obesity and type 2 diabetes: the buffering efficiency hypothesis. Diabetes Care 2011;34(S2):S335-41
   Google Scholar
• Lee JD, Kato K, Tobias PS, et al. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 1992;175(6):1697-705
   Google Scholar
• Haziot A, Rong GW, Bazil V, et al. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol 1994;152(12):5868-76
   Google Scholar
• Haziot A, Rong GW, Lin XY, et al. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995;154(12):6529-32
   Google Scholar
• Roncon-Albuquerque R Jr, Moreira-Rodrigues M, Faria B, et al. Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice. Life Sci 2008;83(13-14):502-10
   PubMed Web of Science ®Google Scholar
• Fernández-Real JM, Pérez del Pulgar S, Luche E, et al. CD14 modulates inflammation-driven insulin resistance. Diabetes 2011;60(8):2179-86
   Google Scholar
• Fernández-Real JM, Broch M, Richart C, et al.14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab 2003;88(4):1780-4
   Google Scholar
• Manco M, Fernandez-Real JM, Vecchio FM, et al. The decrease of serum levels of human neutrophil alpha-defensins parallels with the surgery-induced amelioration of NASH in obesity. Obes Surg 2010;20(12):1682-9
   Google Scholar
• Wang Y, Lam KS, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53(1):34-41
   PubMed Web of Science ®Google Scholar
• Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56(10):2533-40
   PubMedGoogle Scholar
• Jessen BA, Stevens GJ. Expression profiling during adipocyte differentiation of 3T3-L1 fibroblasts. Gene 2002;299(1-2):95-100
   Google Scholar
• Fain JN, Tagele BM, Cheema P, et al. Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women. Obesity (Silver Spring) 2010;18(5):890-6
   Google Scholar
• Koiou E, Tziomalos K, Katsikis I, et al. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecol Endocrinol 2012;28(1):20-4
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Manco M, Ibáñez J, et al. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int J Obes (Lond) 2010;34(2):240-9
   Google Scholar
• Law IK, Xu A, Lam KS, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes 2010;59(4):872-82
   Google Scholar
• Auguet T, Quintero Y, Terra X, et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity (Silver Spring) 2011;19(12):2295-300
   PubMedGoogle Scholar
• Liu X, Hamnvik OP, Petrou M, et al. Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study. Eur J Endocrinol 2011;165(5):805-12
   Google Scholar
• Choi KM, Lee JS, Kim EJ, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008;158(2):203-7
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis 2010;213(2):592-7
   Google Scholar
• Liu JT, Song E, Xu A, et al. Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol 2012;165(2):520-31
   Google Scholar
• Zhang J, Wu Y, Zhang Y, et al. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008;22(6):1416-26
   Google Scholar
• Guo H, Jin D, Zhang Y, et al. Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes 2010;59(6):1376-85
   Google Scholar
• Paton CM, Rogowski MP, Kozimor AL, et al. Lipocalin-2 increases fat oxidation in vitro and is correlated with energy expenditure in normal weight but not obese women. Obesity (Silver Spring) 2013;21(12):E640-8
   Google Scholar
• Jin D, Guo H, Bu SY, et al. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. FASEB J 2011;25(2):754-64
   Google Scholar
• Guo H, Bazuine M, Jin D, et al. Evidence for the regulatory role of lipocalin 2 in high-fat diet-induced adipose tissue remodeling in male mice. Endocrinology 2013;154(10):3525-38
   Google Scholar
• Jun LS, Siddall CP, Rosen ED. A minor role for lipocalin 2 in high-fat diet-induced glucose intolerance. Am J Physiol Endocrinol Metab 2011;301(5):E825-35
   Google Scholar
• Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432(7019):917-21
   PubMed Web of Science ®Google Scholar
• Berger T, Togawa A, Duncan GS, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 2006;103(6):1834-9
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega FJ, Bassols J, et al. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin Endocrinol Metab 2009;94(10):4036-44
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega FJ, Bassols J, et al. Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clin Chem 2008;54(2):301-9
   PubMed Web of Science ®Google Scholar
• Pilvi TK, Harala S, Korpela R, Mervaala EM. Effects of high-calcium diets with different whey proteins on weight loss and weight regain in high-fat-fed C57BL/6J mice. Br J Nutr 2009;102(3):337-41
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega FJ, Ricart W, Fernandez-Real JM. Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced (p473Ser)AKT while impairing adipocyte differentiation. Int J Obes (Lond) 2009;33(9):991-1000
   PubMed Web of Science ®Google Scholar
• Ono T, Murakoshi M, Suzuki N, et al. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 2010;104(11):1688-95
   PubMed Web of Science ®Google Scholar
• Morishita S, Ono T, Fujisaki C, et al. Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice. J Oleo Sci 2013;62(2):97-103
   Google Scholar
• Gubern C, López-Bermejo A, Biarnés J, et al. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability increasing protein. Diabetes 2006;55(1):216-24
   Google Scholar
• Esteve E, Castro A, Moreno JM, et al. Circulating bactericidal/permeability-increasing protein (BPI) is associated with serum lipids and endothelial function. Thromb Haemost 2010;103(4):780-7
   Google Scholar
• López-Bermejo A, Chico-Julià B, Castro A, et al. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2007;27(5):1166-71
   Google Scholar
• Adapala VJ, Buhman KK, Ajuwon KM. Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet. J Inflamm (Lond) 2011;28(8):5
   Google Scholar
• López-Bermejo A, Ortega FJ, Castro A, et al. The alarm secretory leukocyte protease inhibitor increases with progressive metabolic dysfunction. Clin Chim Acta 2011;412(11-12):1122-6
   Google Scholar
• Nijhuis J, Rensen SS, Slaats Y, et al. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring) 2009;17(11):2014-18
   PubMed Web of Science ®Google Scholar
• Mortensen OH, Nielsen AR, Erikstrup C, et al. Calprotectin--a novel marker of obesity. PLoS One 2009;4(10):e7419
   PubMed Web of Science ®Google Scholar
• Elbein SC, Hoffman MD, Teng K, et al. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes 1999;48(5):1175-82
   PubMed Web of Science ®Google Scholar
• Hiuge-Shimizu A, Maeda N, Hirata A, et al. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. Arterioscler Thromb Vasc Biol 2011;31(4):792-9
   Google Scholar
• Nakatsuji H, Kishida K, Funahashi T, Shimomura I; Senri Study II Group. Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity. Diabetes Res Clin Pract 2012;95(3):e58-60
   Google Scholar
• Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 2011;17(11-12):1157-67
   PubMed Web of Science ®Google Scholar
• Ortega FJ, Mercader JM, Moreno-Navarrete JM, et al. Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. J Mol Med (Berl) 2013;91(4):523-34
   PubMed Web of Science ®Google Scholar
• Sekimoto R, Kishida K, Nakatsuji H, et al. High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochem Biophys Res Commun 2012;419(4):782-9
   Google Scholar
• Ortega FJ, Sabater M, Moreno-Navarrete JM, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol 2012;167(4):569-78
   PubMed Web of Science ®Google Scholar
• Yamaoka M, Maeda N, Nakamura S, et al. Gene expression levels of S100 protein family in blood cells are associated with insulin resistance and inflammation (Peripheral blood S100 mRNAs and metabolic syndrome). Biochem Biophys Res Commun 2013;433(4):450-5
   Google Scholar
• Kim SJ, Chae S, Kim H, et al. A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus. Mol Cell Proteomics 2014;13(3):811-22
   PubMed Web of Science ®Google Scholar
• Eckert JK, Kim YJ, Kim JI, et al. The crystal structure of lipopolysaccharide binding protein reveals the location of a frequent mutation that impairs innate immunity. Immunity 2013;39(4):647-60
   PubMed Web of Science ®Google Scholar
• Kirschning CJ, Au-Young J, Lamping N, et al. Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins. Genomics 1997;46(3):416-25
   Google Scholar
• Takeuchi F, Yanai K, Inomata H, et al. Search of type 2 diabetes susceptibility gene on chromosome 20q. Biochem Biophys Res Commun 2007;357(4):1100-6
   Web of Science ®Google Scholar
• Hubacek JA, Pitha J, Skodová Z, et al. Polymorphisms in the lipopolysaccharide-binding protein and bactericidal/permeability-increasing protein in patients with myocardial infarction. Clin Chem Lab Med 2002;40(11):1097-100
   Google Scholar
• Zhan Q, Yuan M, Wang XH, et al. Association of lipopolysaccharide-binding protein gene polymorphisms with cerebral infarction in a Chinese population. J Thromb Thrombolysis 2012;34(2):260-8
   Google Scholar
• Naito E, Yoshida Y, Makino K, et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011;110(3):650-7
   PubMed Web of Science ®Google Scholar
• Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related disorders in apparently healthy Chinese. Diabetes Care 2010;33(9):1925-32
   PubMed Web of Science ®Google Scholar
• Xiao S, Fei N, Pang X, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 2013. [Epub ahead of print]
   Google Scholar
• Kheirandish-Gozal L, Peris E, Wang Y, et al. Lipopolysaccharide-Binding Protein Plasma Levels in Children: effects of Obstructive Sleep Apnea and Obesity. J Clin Endocrinol Metab 2014;99(2):656-63
   PubMed Web of Science ®Google Scholar
• Serrano M, Moreno-Navarrete JM, Puig J, et al. Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. Atherosclerosis 2013;230(2):223-7
   Google Scholar
• Lepper PM, Schumann C, Triantafilou K, et al. Association of lipopolysaccharide binding protein and coronary artery disease in men. J Am Coll Cardiol 2007;50(1):25-31
   Google Scholar
• Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J 2006;13(4):203-10
   PubMedGoogle Scholar
• Inselman LS, Chander A, Spitzer AR. Diminished lung compliance and elevated surfactant lipids and proteins in nutritionally obese young rats. Lung 2004;182(2):101-17
   Google Scholar
• Fernández-Real JM, Chico B, Shiratori M, et al. Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance. Diabetes Care 2008;31(5):958-63
   Google Scholar
• Fernández-Real JM, Valdés S, Manco M, et al. Surfactant protein d, a marker of lung innate immunity, is positively associated with insulin sensitivity. Diabetes Care 2010;33(4):847-53
   Google Scholar
• Pueyo N, Ortega FJ, Mercader JM, et al. Common genetic variants of surfactant protein-D (SP-D) are associated with type 2 diabetes. PLoS One 2013;8(4):e60468
   Google Scholar
• Ortega FJ, Pueyo N, Moreno-Navarrete JM, et al. The lung innate immune gene surfactant protein-D is expressed in adipose tissue and linked to obesity status. Int J Obes (Lond) 2013;37(12):1532-8
   Google Scholar
• Medina-Gomez G, Gray SL, Yetukuri L, et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007;3(4):e64
   PubMed Web of Science ®Google Scholar
• Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117(9):2621-37
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Escoté X, Ortega F, et al. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 2013;56(11):2524-37
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Serrano M, Sabater M, et al. Study of lactoferrin gene expression in human and mouse adipose tissue, human preadipocytes and mouse 3T3-L1 fibroblasts. Association with adipogenic and inflammatory markers. J Nutr Biochem 2013;24(7):1266-75
   Google Scholar
• Moreno-Navarrete JM, Ortega F, Sabater M, et al. Proadipogenic effects of lactoferrin in human subcutaneous and visceral preadipocytes. J Nutr Biochem 2011;22(12):1143-9
   Google Scholar
• Moreno-Navarrete JM, Ortega F, Moreno M, et al. Lactoferrin gene knockdown leads to similar effects to iron chelation in human adipocytes. J Cell Mol Med 2014;18(3):391-5
   Google Scholar
• Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 2012;90(3):252-68
   PubMedGoogle Scholar
• Malet A, Bournaud E, Lan A, et al. Bovine lactoferrin improves bone status of ovariectomized mice via immune function modulation. Bone 2011;48(5):1028-35
   PubMed Web of Science ®Google Scholar
• Naot D, Chhana A, Matthews BG, et al. Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. Bone 2011;49(2):217-24
   Google Scholar
• Ge Q, Gérard J, Noël L, et al. MicroRNAs regulated by adiponectin as novel targets for controlling adipose tissue inflammation. Endocrinology 2012;153(11):5285-96
   Google Scholar
• Nakarai H, Yamashita A, Nagayasu S, et al. Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications. Innate Immun 2012;18(1):164-70
   Google Scholar